In particular, among these two randomized clinical trials (CHECKMATE-227 and CHECKMATE-9LA) showed better efficacy of ipilimumab (a fully human IgG1 mAb targeting CTLA-4) plus nivolumab treatment compared with chemotherapy alone, allowing the FDA approval of the dual checkpoint blockade to treat patients with advanced NSCLC patients, in 2020 (Table 1) [78]. Here, CTLA4 is linked to non-small cell lung carcinoma.